### **POSTER PRESENTATION**



**Open Access** 

# Quantification of cAMP and cGMP analogs in intact cells: pitfals in enzyme immunoassays for cyclic nucleotides

Katharina Werner<sup>1\*</sup>, Frank Schwede<sup>2</sup>, Hans-Gottfried Genieser<sup>2</sup>, Jörg Geiger<sup>1</sup>, Elke Butt<sup>1\*</sup>

*From* 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany. 24-26 June 2011

#### Background

The present work evaluates the cross-reactivity of commercially available cyclic nucleotide analogs with cAMPand cGMP-immunoassays from Cayman, IBL (both IBL International, Hamburg, Germany) and ENZO Life Sciences (Loerrach, Germany).

#### **Results and conclusion**

Most of the tested cyclic nucleotide analogs showed low degree competition with the antibodies; however, with Rp-cAMPS, 8-Br-cGMP and 8-pCPT-cGMP a strong cross-reactivity with the ENZO cAMP- respectively cGMP-EIA and the IBL cGMP-RIA was observed (Table

Analog	Log K <sub>w</sub>	Permeability	Specificity ENZO cAMP-EIA	Specificity ENZO cAMP-EIA	Specificity IBL cGMP-RIA	Specificity Cayman cGMP-EIA
2'-dcGMP	0.65	0%		5.21%		
cGMP	0.77			100%	100%	100%
Rp-cGMPS	0.89			0.27%	10.6%	
2'-dcAMP		0%	2.4%			
cAMP	1.09		100%			
8-Br-cGMP	1.17	12.1%		490%	20%	0.5%
Rp-cAMPS	1.21	12.2%	68%			
8-Br-cAMP	1.35	8.0%	0.4%			
Rp-8-Br-cAMPS	1.47		0.3%			
6-MB-cAMP	1.64		0.4%			
6-Bnz-cAMP	1.9		0.6%			
8-pCPT-cGMP	2.52	19.6%		240%	30%	0.008%
8-pCPT-cAMP	2.65	22.0%	0.05%			
8-Br-PET-cGMP	2.83	30.9%		10%	0.15%	1.6%
Rp-8-Br-PET-cGMPS	2.83			0.2%		
8-pCPT-2'-OMe-cAMP (Epac Activator)	2.94		0.03%	0.02%		
Sp-5,6-DCI-cBIMPS	2.99		<0.001%			

#### Table 1 Lipophilicity (log K<sub>w</sub>), cell permeability and EIA/RIA specificity of selected cyclic Nucleotide analogs.

\* Correspondence: butt@klin-biochem.uni-wuerzburg.de

<sup>1</sup>Institute for Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Germany

Full list of author information is available at the end of the article



© 2011 Werner et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1). As a consequence we tested these derivatives with the Cayman cGMP-EIA. This assay is less sensitive to cGMP (1.0 pmol/ml) than the ENZO cGMP-EIA (0.01 pmol/ml), however the specificity concerning cGMP-analogs is superior and therefore advantageous when measuring cGMP in the presence of 8-Br-cGMP or 8-pCPT-cGMP.

The determined EIA binding constants enabled the measurement of the intracellular cyclic nucleotide concentrations and revealed a time- and lipophilicity-dependent cell membrane permeability of the compounds in the range of 10-30 % of the extracellular applied concentration after 20 min (Table 1).

#### Author details

<sup>1</sup>Institute for Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Germany. <sup>2</sup>Biolog Life Science Institute, Flughafendamm 9a, D-28199 Bremen, Germany.

Published: 1 August 2011

doi:10.1186/1471-2210-11-S1-P75

**Cite this article as:** Werner *et al.*: **Quantification of cAMP and cGMP analogs in intact cells: pitfals in enzyme immunoassays for cyclic nucleotides.** *BMC Pharmacology* 2011 **11**(Suppl 1):P75.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit